icon
موقع حكومي رسمي تابع لحكومة المملكة العربية السعودية
icon الجمعة 12 جمادى الأولى 1448هـ
نسخة تجريبية
icon
روابط المواقع الالكترونية الرسمية السعودية تنتهي بـ gov.sa

جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa

icon
المواقع الرسمية الآمنة تستخدم HTTPS

تحقق من أن الموقع يستخدم بروتوكول HTTPS

icon

مسجل لدى هيئة الحكومة الرقمية برقم :

20250831619
اقتراحات

قائمة الدراسات السريرية المسجلة على الادوية

عرض 181 - 190 من 518
عنوان الدراسة داعم الدراسة حالة الدراسة دواء الدراسة مرحلة الدراسة رقم بروتوكول الدراسة موقع الدراسة
An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Fluca Eye Drops Containing Sodium Cromoglycate (20 mg/ml) and Fluorometholone (1 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fever Jamjoom Pharmaceuticals Completed FLUCA 4 FLUCA001 King Khalid University Hospital (Riyadh)
An open label, Phase IV Multicentric Single Arm Study to Assess the Safety and Efficacy of Croma Ophthalmic Solution Containing Sodium Cromoglycate (40 mg/ml) and Tetrahydrozoline Hydrochloride (0.5 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fever (Seasonal) Jamjoom Pharmaceuticals Completed Croma 4 CROMA001 King Khalid University Hospital (Riyadh)
The Effect of Sulfad tablet on Hepatitis B & C, achieving a sustained response Northren Area Armed Force Hospital Completed Sulfad 3 Protocol dated: 2011 Northren Area Armed Force Hospital
A 26-week, Randomized, Double-blinded, Placebo controlled study to explore the Effects of Probiotics on Endotoxin Levels in patients with Type 2 Diabetes Mellitus "Prince Mutaib bin Abdullah Chair for Biomarkers Research on Osteoporosis" Completed Probiotics 3 STRP-10 King Khalid University Hospital (Riyadh), King Abdulaziz University Hospital (Riyadh), Minstery of Health
Alleviating Post Surgical Dental Pain Julphar Rejected Profinal XP 400 mg F.C Tablet 4 1/2010/PXP/JUL N/A
"Prospective Observational Clinical Practice Study in the 1st LineManagement of mCRC with Erbitux ™ in combination with Chemotherapy" Merck Serono Rejected ERBITUX 4 EMR062202_ N/A
"A prospective, observational, non-randomized, European, multi-centerregistry, collecting REal-life information for the utilization of instantaneouswave-free ratio™ (iFR®) in Assessing coronary stenosis relevance in theMulti-vesseL disease patients population." Volcano Rejected VOLCAO-iFR® 4 2014-CV-00 N/A
A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men who are at High Risk for Poor Clinical Outcomes after Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men with Castration-Resistant Prostate Cancer and Men with Metastatic Prostate Cancer at Initial Diagnosis
Astellas
Rejected 4 ONC-MA1001
N/A
RETROSPECTIVE EPIDEMIOLOGY STUDY OF ALK REARRANGEMENT IN NON-SMALL CELL LUNG CANCER PATIENTS IN THE MIDDLE EAST & NORTH AFRICA Pfizer Rejected - 4 A8081046 N/A
"(LUMINOUS)Study to observe the effectiveness andsafety of ranibizumab through individualized patienttreatment and associated " Novartis Completed Ranibizumab 10mg/ml (Lucentis) 4 RFB002A2406 King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), Prince Sultan Military Medical City (Riyadh)